TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Status:
Not yet recruiting
Trial end date:
2037-02-01
Target enrollment:
Participant gender:
Summary
Despite treatment according to the CROSS-regimen, median overall survival is less than four
years (2.3 QALYs). The burden of disease is within the highest category (0.71 to 1.0). Also,
no targeted treatment options are currently available, hampering personalized treatment for
this patient population. In TRAP-2 we aim to address these needs by investigating whether
addition of trastuzumab and pertuzumab to standard of care improves survival of patients with
resectable HER2 positive esophageal adenocarcinoma (HER2+ EAC). We expect the results to
kick-start the era of personalized medicine for esophageal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)